Record Information |
---|
Version | 5.0 |
---|
Status | Detected but not Quantified |
---|
Creation Date | 2021-09-11 06:42:43 UTC |
---|
Update Date | 2022-11-23 21:54:22 UTC |
---|
HMDB ID | HMDB0249821 |
---|
Secondary Accession Numbers | None |
---|
Metabolite Identification |
---|
Common Name | Ceritinib |
---|
Description | Ceritinib, also known as ZYKADIA, belongs to the class of organic compounds known as phenylpiperidines. Phenylpiperidines are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group. Ceritinib is a very strong basic compound (based on its pKa). Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. However, based on its mechanism of action, ceritinib may cause fetal harm when administered to pregnant women and should therefore be administered with effective contraception during treatment. Drug-induced hepatotoxicity also occurred in 27% of 255 patients, presenting as alanine aminotransferase (ALT) levels greater than 5 times the upper limit of normal (ULN). Diarrhea, nausea, vomiting, or abdominal pain occurred in 96% of 255 patients including severe cases in 14% of patients. Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the enzyme. In vitro studies demonstrated that CYP3A was the major enzyme involved in the metabolic clearance of ceritinib. Following oral administration of a single 750 mg radiolabeled ceritinib dose, ceritinib as the parent compound was the main circulating component (82%) in human plasma. This compound has been identified in human blood as reported by (PMID: 31557052 ). Ceritinib is not a naturally occurring metabolite and is only found in those individuals exposed to this compound or its derivatives. Technically Ceritinib is part of the human exposome. The exposome can be defined as the collection of all the exposures of an individual in a lifetime and how those exposures relate to health. An individual's exposure begins before birth and includes insults from environmental and occupational sources. |
---|
Structure | CC(C)OC1=C(NC2=NC(NC3=CC=CC=C3S(=O)(=O)C(C)C)=C(Cl)C=N2)C=C(C)C(=C1)C1CCNCC1 InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34) |
---|
Synonyms | Value | Source |
---|
Ceritinibum | ChEBI | ZYKADIA | ChEBI | 5-Chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,4-diamine | MeSH |
|
---|
Chemical Formula | C28H36ClN5O3S |
---|
Average Molecular Weight | 558.14 |
---|
Monoisotopic Molecular Weight | 557.2227389 |
---|
IUPAC Name | 5-chloro-N2-[5-methyl-4-(piperidin-4-yl)-2-(propan-2-yloxy)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine |
---|
Traditional Name | 5-chloro-N2-[2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl]-N4-[2-(propane-2-sulfonyl)phenyl]pyrimidine-2,4-diamine |
---|
CAS Registry Number | Not Available |
---|
SMILES | CC(C)OC1=C(NC2=NC(NC3=CC=CC=C3S(=O)(=O)C(C)C)=C(Cl)C=N2)C=C(C)C(=C1)C1CCNCC1 |
---|
InChI Identifier | InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34) |
---|
InChI Key | VERWOWGGCGHDQE-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as phenylpiperidines. Phenylpiperidines are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Piperidines |
---|
Sub Class | Phenylpiperidines |
---|
Direct Parent | Phenylpiperidines |
---|
Alternative Parents | |
---|
Substituents | - Phenylpiperidine
- Benzenesulfonyl group
- Phenoxy compound
- Phenol ether
- Aniline or substituted anilines
- Alkyl aryl ether
- Aminopyrimidine
- Halopyrimidine
- Toluene
- Aralkylamine
- Aryl chloride
- Aryl halide
- Monocyclic benzene moiety
- Pyrimidine
- Benzenoid
- Imidolactam
- Heteroaromatic compound
- Sulfonyl
- Sulfone
- Secondary amine
- Azacycle
- Secondary aliphatic amine
- Ether
- Amine
- Organochloride
- Organohalogen compound
- Organopnictogen compound
- Organonitrogen compound
- Organooxygen compound
- Organic oxygen compound
- Organosulfur compound
- Organic oxide
- Hydrocarbon derivative
- Organic nitrogen compound
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | Not Available |
---|
Disposition | |
---|
Process | Not Available |
---|
Role | Not Available |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Experimental Chromatographic Properties | Not Available |
---|
Predicted Molecular Properties | | Show more...
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatizedDerivatizedDerivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
---|
ceritinib,1TMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCNCC1 | 4140.4 | Semi standard non polar | 33892256 | ceritinib,1TMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCNCC1 | 3855.6 | Standard non polar | 33892256 | ceritinib,1TMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCNCC1 | 5847.6 | Standard polar | 33892256 | ceritinib,1TMS,isomer #2 | CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)=C(OC(C)C)C=C1C1CCNCC1 | 4139.8 | Semi standard non polar | 33892256 | ceritinib,1TMS,isomer #2 | CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)=C(OC(C)C)C=C1C1CCNCC1 | 3966.6 | Standard non polar | 33892256 | ceritinib,1TMS,isomer #2 | CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)=C(OC(C)C)C=C1C1CCNCC1 | 5728.8 | Standard polar | 33892256 | ceritinib,1TMS,isomer #3 | CC1=CC(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC1 | 4457.6 | Semi standard non polar | 33892256 | ceritinib,1TMS,isomer #3 | CC1=CC(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC1 | 4057.4 | Standard non polar | 33892256 | ceritinib,1TMS,isomer #3 | CC1=CC(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC1 | 6146.9 | Standard polar | 33892256 | ceritinib,2TMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCNCC1 | 4030.8 | Semi standard non polar | 33892256 | ceritinib,2TMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCNCC1 | 4055.9 | Standard non polar | 33892256 | ceritinib,2TMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCNCC1 | 5284.5 | Standard polar | 33892256 | ceritinib,2TMS,isomer #2 | CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC1 | 4263.6 | Semi standard non polar | 33892256 | ceritinib,2TMS,isomer #2 | CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC1 | 4134.5 | Standard non polar | 33892256 | ceritinib,2TMS,isomer #2 | CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC1 | 5701.9 | Standard polar | 33892256 | ceritinib,2TMS,isomer #3 | CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC1 | 4252.2 | Semi standard non polar | 33892256 | ceritinib,2TMS,isomer #3 | CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC1 | 4242.7 | Standard non polar | 33892256 | ceritinib,2TMS,isomer #3 | CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC1 | 5599.7 | Standard polar | 33892256 | ceritinib,3TMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC1 | 4159.2 | Semi standard non polar | 33892256 | ceritinib,3TMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC1 | 4322.4 | Standard non polar | 33892256 | ceritinib,3TMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C)=N2)[Si](C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C)CC1 | 5199.4 | Standard polar | 33892256 | ceritinib,1TBDMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCNCC1 | 4342.0 | Semi standard non polar | 33892256 | ceritinib,1TBDMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCNCC1 | 4079.4 | Standard non polar | 33892256 | ceritinib,1TBDMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCNCC1 | 5813.4 | Standard polar | 33892256 | ceritinib,1TBDMS,isomer #2 | CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)=C(OC(C)C)C=C1C1CCNCC1 | 4349.3 | Semi standard non polar | 33892256 | ceritinib,1TBDMS,isomer #2 | CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)=C(OC(C)C)C=C1C1CCNCC1 | 4199.7 | Standard non polar | 33892256 | ceritinib,1TBDMS,isomer #2 | CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)=C(OC(C)C)C=C1C1CCNCC1 | 5710.1 | Standard polar | 33892256 | ceritinib,1TBDMS,isomer #3 | CC1=CC(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC1 | 4672.0 | Semi standard non polar | 33892256 | ceritinib,1TBDMS,isomer #3 | CC1=CC(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC1 | 4249.5 | Standard non polar | 33892256 | ceritinib,1TBDMS,isomer #3 | CC1=CC(NC2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC1 | 6198.3 | Standard polar | 33892256 | ceritinib,2TBDMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCNCC1 | 4397.0 | Semi standard non polar | 33892256 | ceritinib,2TBDMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCNCC1 | 4508.0 | Standard non polar | 33892256 | ceritinib,2TBDMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCNCC1 | 5277.1 | Standard polar | 33892256 | ceritinib,2TBDMS,isomer #2 | CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC1 | 4634.5 | Semi standard non polar | 33892256 | ceritinib,2TBDMS,isomer #2 | CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC1 | 4548.0 | Standard non polar | 33892256 | ceritinib,2TBDMS,isomer #2 | CC1=CC(N(C2=NC=C(Cl)C(NC3=CC=CC=C3S(=O)(=O)C(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC1 | 5718.4 | Standard polar | 33892256 | ceritinib,2TBDMS,isomer #3 | CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC1 | 4620.6 | Semi standard non polar | 33892256 | ceritinib,2TBDMS,isomer #3 | CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC1 | 4672.6 | Standard non polar | 33892256 | ceritinib,2TBDMS,isomer #3 | CC1=CC(NC2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC1 | 5631.3 | Standard polar | 33892256 | ceritinib,3TBDMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC1 | 4682.7 | Semi standard non polar | 33892256 | ceritinib,3TBDMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC1 | 4965.9 | Standard non polar | 33892256 | ceritinib,3TBDMS,isomer #1 | CC1=CC(N(C2=NC=C(Cl)C(N(C3=CC=CC=C3S(=O)(=O)C(C)C)[Si](C)(C)C(C)(C)C)=N2)[Si](C)(C)C(C)(C)C)=C(OC(C)C)C=C1C1CCN([Si](C)(C)C(C)(C)C)CC1 | 5248.1 | Standard polar | 33892256 |
| Show more...
---|